Lung Cancer Trials Ask AI to find trials
UnknownPhase 1NCT04052412
Official study title

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

Study summary

This study is to assess the biodistribution and kinetics of a novel T-cell imaging agent in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy. This study is assessing the change in kinetics that occurs in this patient population to better understand the distribution of this compound in patient disease circumstances.

Ask AI to explain this study
Start here

Key things to know

Main goalBasic Science

This describes the study’s primary purpose.

What is being studied18F-AraG

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 13, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Tennessee

Study sponsor

01
Study overview

What this study is about

Purpose
Basic Science
Study type
Interventional
Phase
Phase 1
Sponsor
University of Tennessee
Interventions being studied
Drug: 18F-AraG
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→Radiation therapy→
Study topics
After surgery (adjuvant)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • This study is open to all adult subjects with histological confirmation of NSCLC enrolled in the parent protocol.
  • Age 21 years of age or greater
  • ECOG performance status of 0, 1, 2 or 3 at the time of enrollment.
  • Patient with life expectancy ≥ 24 weeks from the time of screening to the study
  • Ability to give informed consent
Reasons someone may not be able to joinExclusion criteria
  • Patients with severe claustrophobia (patients with milder forms of claustrophobia that can be successfully allayed with oral anxiolytic therapy are allowed).
  • Severe impaired renal function with estimated glomerular filtration rate \<30 mL/min/1.73 m2 and/or on dialysis.
  • Pregnancy
  • Breast Feeding an infant
  • Unable to tolerate the expected radiation therapy prescription

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Tennessee Medical CenterKnoxville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 13, 2022. Always confirm current availability with the study team.

View original record ↗